Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Zelboraf vemurafenib: Phase I data

Data from 6 metastatic melanoma patients with V600E BRAF mutations in the first cohort of a Phase I trial showed that twice-daily oral 960 mg Zelboraf vemurafenib plus 3 mg/kg Yervoy

Read the full 315 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE